Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Gyre Therapeutics, Inc. has 4 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Gyre Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Distributors are our direct customers, and sales to distributors accounted for 100.0% of the revenue from each of ETUARY®, Etorel® and Contiva®.”
$117M relationship
basisGYRE fy2025 · closed 2025-12 $117M
FILING10-K0001193125-26-106251cik 0001124105
“In May 2024, Gyre Pharmaceuticals entered into a comprehensive agreement with Jiangsu Wangao Pharmaceuticals Co., Ltd. to obtain the drug registration certificate for Etorel® (nintedanib) and become the marketing authorization holder in the PRC.”
FILING10-K0001193125-26-106251cik 0001124105
“In June 2021, Gyre Pharmaceuticals acquired avatrombopag maleate tablets pursuant to a transfer agreement with Nanjing Healthnice Pharmaceutical Technology Co., Ltd.”
FILING10-K0001193125-26-106251cik 0001124105
“The manufacturing of Hydronidone active pharmaceutical ingredients ("API") and drug product required to support the planned Phase 2 clinical trial will be completed by WuXi STA, located in the PRC.”
FILING10-K0001193125-26-106251cik 0001124105
“Through in-house R&D efforts and collaborative arrangements with GNI Group, Ltd. ("GNI Japan"), we have developed, in addition to ETUARY®, a pipeline of pharmaceutical product candidates at various phases of clinical development, including Hydronidone, F528, F230 and F573.”
FILING10-K0001193125-26-106251cik 0001124105
Watchlist prices, news filtered to it, and its next report on your desk.
Gyre Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
GYRE (Gyre Therapeutics, Inc.) has 4 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Prev close 6.99 · gapped below the open, never looked back. High/low 6.81 at 7:00 am ET, 6.48 at 10:15 am ET.